Viral Vectors & Plasmid DNA Manufacturing Market Set to Reach USD 19.22 Billion by 2033 - Gene Therapy Boom, mRNA Advancements & CDMO Expansion Drive Unprecedented Demand
The global viral vectors & plasmid DNA manufacturing market size is valued at USD 6.38 billion in 2025 and is predicted to increase from USD 7.24 billion in 2026 to approximately USD 19.22 billion by 2033, growing at a CAGR of 14.90% from 2026 to 2033. A rapidly expanding gene and cell therapy pipeline, rising demand for GMP-compliant manufacturing, and breakthrough approvals across oncology, rare diseases, and inherited disorders are reshaping how the life science industry approaches biological drug production. H OUSTON, Texas, United States, June 2026 — As gene and cell therapy transitions from clinical innovation to commercial reality, the viral vectors & plasmid DNA manufacturing market is becoming a strategic priority for biopharmaceutical executives, CDMO investors, and healthcare policymakers worldwide. With over 4,000 advanced therapies currently in development and the FDA projecting 10 to 20 cell and gene therapy approvals per year, the demand for scalable, hig...